These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 23128399

  • 1. Natalizumab: bench to bedside and beyond.
    Rudick R, Polman C, Clifford D, Miller D, Steinman L.
    JAMA Neurol; 2013 Feb; 70(2):172-82. PubMed ID: 23128399
    [Abstract] [Full Text] [Related]

  • 2. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE.
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [Abstract] [Full Text] [Related]

  • 3. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 4. Natalizumab (Tysabri) returns.
    Med Lett Drugs Ther; 2006 Sep 11; 48(1243):76. PubMed ID: 16977289
    [No Abstract] [Full Text] [Related]

  • 5. Treating multiple sclerosis with natalizumab.
    Iaffaldano P, Lucchese G, Trojano M.
    Expert Rev Neurother; 2011 Dec 11; 11(12):1683-92. PubMed ID: 22091593
    [Abstract] [Full Text] [Related]

  • 6. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
    Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T.
    Mult Scler; 2012 Feb 11; 18(2):143-52. PubMed ID: 22312009
    [Abstract] [Full Text] [Related]

  • 7. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Feb 11; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 8. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A, Tintoré M.
    Neurologia; 2011 Feb 11; 26(6):357-68. PubMed ID: 21193250
    [Abstract] [Full Text] [Related]

  • 9. Multiple sclerosis, natalizumab, and PML: helping patients decide.
    Rudick RA.
    Cleve Clin J Med; 2011 Nov 11; 78 Suppl 2():S18-23. PubMed ID: 22123928
    [Abstract] [Full Text] [Related]

  • 10. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A.
    Neurology; 2012 May 29; 78(22):1736-42. PubMed ID: 22592369
    [Abstract] [Full Text] [Related]

  • 11. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
    Boster AL, Nicholas JA, Topalli I, Kisanuki YY, Pei W, Morgan-Followell B, Kirsch CF, Racke MK, Pitt D.
    JAMA Neurol; 2013 Mar 01; 70(3):398-402. PubMed ID: 23338729
    [Abstract] [Full Text] [Related]

  • 12. Natalizumab (tysabri)-associated progressive multifocal leukoencephalopathy: insights from perfusion magnetic resonance imaging.
    Elster MJ.
    J Comput Assist Tomogr; 2013 Mar 01; 37(5):694-7. PubMed ID: 24045242
    [Abstract] [Full Text] [Related]

  • 13. Lessons for clinical trials from natalizumab in multiple sclerosis.
    Chaudhuri A.
    BMJ; 2006 Feb 18; 332(7538):416-9. PubMed ID: 16484271
    [Abstract] [Full Text] [Related]

  • 14. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb 18; 17(93):7-10. PubMed ID: 18354844
    [Abstract] [Full Text] [Related]

  • 15. Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
    Landy DC, Hecht EM.
    Clin Neuropharmacol; 2014 Feb 18; 37(2):45-51. PubMed ID: 24614671
    [Abstract] [Full Text] [Related]

  • 16. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
    Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M.
    Ann Neurol; 2012 Nov 18; 72(5):779-87. PubMed ID: 23280794
    [Abstract] [Full Text] [Related]

  • 17. Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy.
    Serana F, Chiarini M, Sottini A, Bertoli D, Giustini V, Tessitore MV, Caimi L, Capra R, Imberti L.
    J Neuroimmunol; 2014 Dec 15; 277(1-2):6-12. PubMed ID: 25468273
    [Abstract] [Full Text] [Related]

  • 18. Natalizumab: Perspectives from the Bench to Bedside.
    Shirani A, Stüve O.
    Cold Spring Harb Perspect Med; 2018 Dec 03; 8(12):. PubMed ID: 29500304
    [Abstract] [Full Text] [Related]

  • 19. Natalizumab therapy for multiple sclerosis.
    Derfuss T, Kuhle J, Lindberg R, Kappos L.
    Semin Neurol; 2013 Feb 03; 33(1):26-36. PubMed ID: 23709210
    [Abstract] [Full Text] [Related]

  • 20. Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
    Décard BF, Haghikia A, Tönnes C, Thöne J, Lukas C, Chan A, Gold R.
    Mult Scler; 2013 Feb 03; 19(2):249-51. PubMed ID: 22596228
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.